An anti-neoplastic glycan isolated from Mycobacterium bovis (BCG vaccine).
Tice substrain BCG is used clinically as an immunotherapeutic agent against superficial bladder cancer. A boiling-water extract of this BCG showed anti-tumour activity against a murine S180 sarcoma model and was fractionated into three fractions, A, B and C, by the use of Sephadex LH-20 chromatography. An anti-tumour glucan, PS1A1, was isolated from fraction PS1A with Sephadex G-75. The molecular mass of PS1A1 was between 65 and 87 kDa by Sephadex G-100 chromatography. The structure of PS1A1 was investigated by one- and two-dimensional NMR spectroscopy and methylation analysis and was demonstrated to be primarily 1-->6-alpha-linked glucose units. We postulate that the repeating unit is: [Formula: see text]
D000818:Animals; D000970:Antineoplastic Agents / Q000032:analysis* / Q000302:isolation & purification / Q000494:pharmacology*; D001500:BCG Vaccine / Q000737:chemistry*; D002240:Carbohydrate Sequence; D002849:Chromatography, Gas; D004354:Drug Screening Assays, Antitumor; D005260:Female; D005936:Glucans / Q000032:analysis* / Q000302:isolation & purification / Q000494:pharmacology*; D051379:Mice; D008969:Molecular Sequence Data; D011134:Polysaccharides / Q000032:analysis* / Q000302:isolation & purification / Q000494:pharmacology*; D012510:Sarcoma 180 / Q000188:drug therapy
D000970:Antineoplastic Agents; D001500:BCG Vaccine; D005936:Glucans; C096802:PS1A1 glucan; D011134:Polysaccharides